Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 71.01M shares rose 11.8% year over year, ahead of the +5.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +11.8% holds above the trailing-twelve-month pace of +5.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
71.01M+0.7% QoQ
Last fiscal yearDec 2025
63.57M-2.3% YoY
LTMJun 2026
67.21M+5.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.8%——
1 year-2.3%——
3-year CAGR+9.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
63.57M USD
Year-over-year change
-2.3%
4-year CAGR
+8.2%

Weighted Avg Shares (Diluted) vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's LTM Jun 2026 weighted avg shares (diluted) of 67.21M shares is the 4th highest of the 7 companies compared; the peer median is 81.01M shares.
  • Its year-over-year change of +5.6% is the 6th highest of 7, against a peer median of +30.9%.
  • Over three fiscal years its annual growth of +9.0% compares with a peer median of +46.6%.
PTGX Competitors Peer median
Weighted Avg Shares (Diluted) for PTGX and competitors
Company Period LTM YoY 3-year CAGR
IMVTImmunovant, Inc.LTM Sep 2026199.36M +24.0%+14.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
PTGXProtagonist Therapeutics, Inc.LTM Jun 202667.21M +5.6%+9.0%
IRONDisc Medicine, Inc.LTM Sep 202637.84M +13.4%+223.8%
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding PTGX) 81.01M+30.9%+46.6%

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.36M26.58M60M434.43M46.02M
Cost of Revenue00001.23M
Gross Profit27.36M26.58M60M434.43M44.79M
Gross Margin100.0%100.0%100.0%100.0%97.3%
Research & Development126.01M126.22M120.16M138.13M159.29M
Selling, General & Admin27.2M31.74M33.49M43.46M44.85M
Operating Expenses153.2M157.95M153.65M181.59M202.92M
Depreciation & Amortization2.78M3.37M3.31M2.96M1.28M
EBITDA(122.78M)(124.02M)(75.64M)282.37M(128.03M)
EBITDA Margin-448.8%-466.6%-126.1%65.0%-278.2%
Operating Income(125.85M)(131.37M)(93.65M)252.84M(158.13M)
Operating Margin-460.0%-494.2%-156.1%58.2%-343.6%
Interest Income443K4.06M14.9M26.32M28.79M
Interest Expense00000
Other Income / Expenses294K3.98M14.7M26.57M28.82M
Income Before Tax(125.55M)(127.39M)(78.96M)279.41M(129.31M)
Pre-Tax Margin-458.9%-479.3%-131.6%64.3%-281.0%
Income Tax Expense0004.22M838K
Net Income(125.55M)(127.39M)(78.96M)275.19M(130.15M)
Net Margin-458.9%-479.3%-131.6%63.3%-282.8%
EPS (Basic)(2.65)(2.52)(1.39)4.47(2.05)
EPS (Diluted)(2.65)(2.52)(1.39)4.23(2.05)
Weighted Avg Shares46.32M49.04M56.76M61.57M63.57M
Weighted Avg Shares (Diluted)46.32M49.04M56.76M65.08M63.57M

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.